Regulatory reference
KIMADIA 2023 dialysis tenders: specified FDA/CE evidence, not a national registration rule
- Statement
KIMADIA tenders 55/2023/84 and 55/2023/85 for the national hemodialysis project specify FDA/CE quality evidence for the covered equipment. This dated tender document does not establish the requirements of every Iraqi procurement or private-sector registration. Its Arabic/English wording also differs at item 2, so the procurer should resolve the exact tender requirement.
- Source Jurisdiction Id
china
- Source Authority Id
nmpa
- Source Approval
China NMPA medical device registration certificate (Class II/III) or Class I filing record
- Target Jurisdiction Id
iraq
- China Classes In Scope
Equipment covered by these two 2023 dialysis tenders only
- Edge Type
Eligibility Unresolved
- Market Access Strength
undetermined
- Regulatory Layer
Public Procurement
- Local Application Required
Yes
- Target Decision Retained
Yes
- Historical tender-specific evidence; current procurement and private-market requirements are unconfirmed.
- Do not generalise this tender to all medical devices or IVDs in Iraq.
- Independent verification is incomplete. Treat this record as a research lead, not a confirmed benefit or exclusion; see the 2026-09-15 independent review.
Source passage: على ان تكون الاجهزة حاصلة على شهادات (FDA or CE) ومصنعة من قبل شركات عالمية رصينة وحسب المواصفات الفنية المعتمدة من قبل دائرة الامور الفنية / قسم ادارة الاجهزة الطبية ... 34- تكون الاجهزة الطبية الاساسية والملحقة والاجهزة المختبرية حاصلة على شهادة الجودة (FDA or CE).

